CELMoDs And The Future Of Multiple Myeloma Care
- Revlimid has long been a cornerstone of multiple myeloma treatment, used from initial therapy through long-term maintenance.
- Newer drugs called CELMoDs are designed to work the same way, but more powerfully. “They’re sort of like a more potent, ‘super’ Revlimid,” Dr. Melissa Alsina, head of the Multiple Myeloma Transplant Program at Moffitt Cancer Center, tells SurvivorNet.
- Early research suggests this newer class of drugs may work even when Revlimid stops being effective. Because so many patients receive Revlimid early and continuously, doctors are increasingly seeing cancers that become resistant to it.
- Right now, CELMoDs are being studied in patients whose cancer has returned after prior treatment, but their role could expand.
For decades, Revlimid has been a cornerstone of care, used both in early treatment and long-term maintenance.
Read MoreRevlimid’s Current Role in Multiple Myeloma Care
Revlimid is commonly used as part of first-line (initial) treatment, often in a four-drug combination.Revlimid is given alongside:
- An antibody like daratumumab
- A proteasome inhibitor such as bortezomib or carfilzomib
- A steroid (dexamethasone)
Together, these regimens are designed to get the disease under control quickly and deeply.
After initial treatment, and often after a stem cell transplant, patients typically continue therapy to keep the cancer from returning. This is called maintenance therapy, and Revlimid has been the most studied and widely used drug in this setting.
“We know maintenance is important… and Revlimid has been shown to be very effective,” Dr. Alsina says.
It’s given as a low-dose pill, and most patients tolerate it well over time. The most common side effects include gastrointestinal issues, like diarrhea, and lower blood counts (cytopenias).
For many patients, these side effects are manageable, allowing them to stay on treatment long-term.
What Are CELMoDs?
Even with its success, Revlimid has limitations. Over time, the disease can stop responding. Because so many patients receive it early and continuously, doctors are increasingly seeing cancers that become resistant to it.
That’s where CELMoDs (cereblon E3 ligase modulators) come in.
CELMoDs are designed to work like Revlimid, but more powerfully.
“They’re sort of like a more potent, ‘super’ Revlimid,” Dr. Alsina explains.
Two leading drugs in this group are:
- iberdomide
- mezigdomide
Like Revlimid, they are oral drugs. They have similar side effects, such as low blood counts and gastrointestinal symptoms, but may be more effective.
So far, when used alone in patients whose disease has come back, these drugs show modest response rates — around 30 to 40%.
But the real promise appears when they are combined with other treatments, where they seem to work much better. Early research suggests they can still be active even in patients who have already been treated with multiple other therapies.
The Future Of Multiple Myeloma Care
Right now, CELMoDs are being studied in patients whose cancer has returned after prior treatment, but their role could expand.
They may replace older drugs like pomalidomide in later lines of therapy, move earlier in treatment, and even challenge Revlimid as the standard for maintenance.
In fact, some studies are already comparing these newer drugs directly to Revlimid in the maintenance setting. There are also trials testing them as part of the same four-drug combinations used in newly diagnosed patients, potentially replacing Revlimid there as well.
The treatment landscape for multiple myeloma is evolving quickly. There’s no longer just one standard approach. Instead, patients and doctors have more options and more decisions to make.
Treatment choices are made based on several factors, such as:
- How aggressive the disease is
- What therapies a patient has already received
- Side effects and quality of life
As the treatment options evolve, CELMoDs may play a larger role in care, as Revlimid has for years.
“Five or ten years from now, it may not be Revlimid. It may be one of these newer drugs,” Dr. Alsina says.
Questions To Ask Your Doctor
- Is Revlimid the best option for my care?
- Are there clinical trials testing newer drugs I should consider?
- If my cancer comes back, should I consider a CELMoD?
- What are the risks/benefits of trying out a newer drug?
Learn more about SurvivorNet's rigorous medical review process.
